Infusystem Hld Financials
This page shows Infusystem Hld (INFU) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Infusystem Hld has an operating margin of 8.3%, meaning the company retains $8 of operating profit per $100 of revenue. This results in a moderate score of 41/100, indicating healthy but not exceptional operating efficiency. This is up from 5.1% the prior year.
Infusystem Hld's revenue grew 6.4% year-over-year to $143.4M, a solid pace of expansion. This earns a growth score of 44/100.
Infusystem Hld carries a low D/E ratio of 0.34, meaning only $0.34 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 95/100, indicating a strong balance sheet with room for future borrowing.
Infusystem Hld's current ratio of 1.80 indicates adequate short-term liquidity, earning a score of 32/100. The company can meet its near-term obligations, though with limited headroom.
Infusystem Hld converts 16.6% of revenue into free cash flow ($23.8M). This strong cash generation earns a score of 67/100.
Infusystem Hld's ROE of 11.6% shows moderate profitability relative to equity, earning a score of 37/100. This is up from 4.1% the prior year.
Infusystem Hld scores 3.77, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($187.8M) relative to total liabilities ($43.2M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Infusystem Hld passes 8 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Infusystem Hld generates $3.68 in operating cash flow ($24.4M OCF vs $6.6M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Infusystem Hld earns $9.2 in operating income for every $1 of interest expense ($11.9M vs $1.3M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
Infusystem Hld generated $143.4M in revenue in fiscal year 2025. This represents an increase of 6.4% from the prior year.
Infusystem Hld's EBITDA was $25.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 30.0% from the prior year.
Infusystem Hld reported $6.6M in net income in fiscal year 2025. This represents an increase of 182.6% from the prior year.
Infusystem Hld earned $0.31 per diluted share (EPS) in fiscal year 2025. This represents an increase of 181.8% from the prior year.
Cash & Balance Sheet
Infusystem Hld generated $23.8M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 23.1% from the prior year.
Infusystem Hld held $3.2M in cash against $19.6M in long-term debt as of fiscal year 2025.
Infusystem Hld had 20M shares outstanding in fiscal year 2025. This represents a decrease of 5.0% from the prior year.
Margins & Returns
Infusystem Hld's gross margin was 56.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 3.8 percentage points from the prior year.
Infusystem Hld's operating margin was 8.3% in fiscal year 2025, reflecting core business profitability. This is up 3.2 percentage points from the prior year.
Infusystem Hld's net profit margin was 4.6% in fiscal year 2025, showing the share of revenue converted to profit. This is up 2.9 percentage points from the prior year.
Infusystem Hld's ROE was 11.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 7.5 percentage points from the prior year.
Capital Allocation
Infusystem Hld spent $9.9M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents an increase of 736.4% from the prior year.
Infusystem Hld invested $560K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 48.7% from the prior year.
INFU Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $36.2M-0.7% | $36.5M+1.3% | $36.0M+3.7% | $34.7M+2.6% | $33.8M-4.2% | $35.3M+4.8% | $33.7M+5.3% | $32.0M |
| Cost of Revenue | $15.8M+0.8% | $15.7M-2.9% | $16.1M+3.7% | $15.5M-0.5% | $15.6M-4.0% | $16.3M-4.4% | $17.0M+9.7% | $15.5M |
| Gross Profit | $20.4M-1.8% | $20.8M+4.8% | $19.9M+3.7% | $19.2M+5.2% | $18.2M-4.4% | $19.0M+14.3% | $16.7M+1.2% | $16.5M |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | $14.1M-2.4% | $14.4M+9.8% | $13.1M-14.2% | $15.3M+15.9% | $13.2M+3.4% | $12.8M+10.9% | $11.5M-15.9% | $13.7M |
| Operating Income | $3.7M-2.5% | $3.8M+0.9% | $3.8M+511.2% | $618K-76.4% | $2.6M-19.9% | $3.3M+76.0% | $1.9M+319.5% | -$845K |
| Interest Expense | $260K-21.2% | $330K-11.5% | $373K+11.0% | $336K-6.9% | $361K-24.2% | $476K-1.7% | $484K+6.1% | $456K |
| Income Tax | $1.5M+25.1% | $1.2M+37.9% | $847K+62.9% | $520K-60.9% | $1.3M+36.1% | $978K+65.5% | $591K+417.7% | -$186K |
| Net Income | $2.0M-9.9% | $2.3M-13.1% | $2.6M+1073.4% | -$267K-128.6% | $933K-48.4% | $1.8M+152.0% | $717K+164.5% | -$1.1M |
| EPS (Diluted) | N/A | $0.11-8.3% | $0.12+1300.0% | $-0.01 | N/A | $0.08+166.7% | $0.03+160.0% | $-0.05 |
INFU Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $100.6M+1.7% | $98.9M-2.0% | $100.8M-3.3% | $104.3M+0.6% | $103.6M-1.6% | $105.3M-3.0% | $108.5M+3.5% | $104.8M |
| Current Assets | $36.3M+2.2% | $35.6M+2.2% | $34.8M-1.5% | $35.3M+9.8% | $32.2M-4.3% | $33.6M+2.1% | $32.9M+1.4% | $32.5M |
| Cash & Equivalents | $3.2M+233.6% | $955K+32.6% | $720K-52.2% | $1.5M+185.8% | $527K+38.7% | $380K+160.3% | $146K-82.2% | $822K |
| Inventory | $5.4M-3.6% | $5.6M-1.4% | $5.7M-7.0% | $6.1M-6.6% | $6.5M-2.6% | $6.7M-2.0% | $6.8M+9.4% | $6.2M |
| Accounts Receivable | $22.9M-5.8% | $24.3M-0.7% | $24.5M+2.5% | $23.9M+12.9% | $21.2M-7.1% | $22.8M+6.7% | $21.3M+3.8% | $20.5M |
| Goodwill | $3.7M0.0% | $3.7M0.0% | $3.7M0.0% | $3.7M0.0% | $3.7M0.0% | $3.7M0.0% | $3.7M0.0% | $3.7M |
| Total Liabilities | $43.2M-0.4% | $43.4M-6.3% | $46.3M-5.7% | $49.1M+6.6% | $46.1M-7.4% | $49.8M-9.5% | $55.0M+4.7% | $52.6M |
| Current Liabilities | $20.2M+7.8% | $18.7M+18.0% | $15.9M-0.7% | $16.0M-9.6% | $17.7M+4.3% | $16.9M+6.6% | $15.9M-8.3% | $17.3M |
| Long-Term Debt | $19.6M-6.2% | $20.9M-20.6% | $26.3M-8.2% | $28.7M+20.3% | $23.9M-14.7% | $28.0M-18.1% | $34.2M+14.1% | $29.9M |
| Total Equity | $57.3M+3.3% | $55.5M+1.7% | $54.5M-1.1% | $55.1M-4.1% | $57.5M+3.6% | $55.5M+3.8% | $53.5M+2.3% | $52.3M |
| Retained Earnings | -$60.7M+1.2% | -$61.4M+0.1% | -$61.5M-1.5% | -$60.6M-5.5% | -$57.5M+1.3% | -$58.2M+1.9% | -$59.3M+0.7% | -$59.7M |
INFU Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $7.1M-16.1% | $8.5M+21.2% | $7.0M+293.8% | $1.8M-77.6% | $7.9M-19.4% | $9.8M+326.2% | $2.3M+512.5% | $377K |
| Capital Expenditures | $133K+68.4% | $79K-63.6% | $217K+65.6% | $131K-75.3% | $530K+1132.6% | $43K-87.2% | $337K+85.2% | $182K |
| Free Cash Flow | $7.0M-16.9% | $8.4M+23.9% | $6.8M+311.9% | $1.6M-77.7% | $7.4M-24.5% | $9.8M+396.9% | $2.0M+911.3% | $195K |
| Investing Cash Flow | -$2.2M-769.8% | -$252K+85.0% | -$1.7M+36.7% | -$2.7M+18.6% | -$3.3M-14.5% | -$2.9M+57.3% | -$6.7M-1501.9% | -$418K |
| Financing Cash Flow | -$2.7M+66.2% | -$8.0M-31.0% | -$6.1M-428.5% | $1.9M+141.2% | -$4.5M+33.1% | -$6.8M-281.9% | $3.7M+487.2% | $632K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | $1.3M-39.8% | $2.2M-38.1% | $3.5M+20.9% | $2.9M+1354.8% | $199K-71.5% | $698K+146.6% | $283K | $0 |
INFU Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 56.4%-0.7pp | 57.1%+1.9pp | 55.2%0.0pp | 55.2%+1.4pp | 53.8%-0.1pp | 53.9%+4.5pp | 49.5%-2.0pp | 51.5% |
| Operating Margin | 10.3%-0.2pp | 10.4%-0.0pp | 10.5%+8.7pp | 1.8%-5.9pp | 7.7%-1.5pp | 9.2%+3.7pp | 5.5%+8.1pp | -2.6% |
| Net Margin | 5.6%-0.6pp | 6.2%-1.0pp | 7.2%+8.0pp | -0.8%-3.5pp | 2.8%-2.4pp | 5.1%+3.0pp | 2.1%+5.6pp | -3.5% |
| Return on Equity | 3.5%-0.5pp | 4.1%-0.7pp | 4.8%+5.3pp | -0.5%-2.1pp | 1.6%-1.6pp | 3.3%+1.9pp | 1.3%+3.5pp | -2.1% |
| Return on Assets | 2.0%-0.3pp | 2.3%-0.3pp | 2.6%+2.8pp | -0.3%-1.2pp | 0.9%-0.8pp | 1.7%+1.1pp | 0.7%+1.7pp | -1.1% |
| Current Ratio | 1.80-0.1 | 1.90-0.3 | 2.19-0.0 | 2.21+0.4 | 1.82-0.2 | 1.98-0.1 | 2.07+0.2 | 1.87 |
| Debt-to-Equity | 0.34-0.0 | 0.38-0.1 | 0.48-0.0 | 0.52+0.1 | 0.41-0.1 | 0.50-0.1 | 0.64+0.1 | 0.57 |
| FCF Margin | 19.3%-3.8pp | 23.1%+4.2pp | 18.9%+14.1pp | 4.8%-17.1pp | 21.9%-5.9pp | 27.7%+21.9pp | 5.9%+5.2pp | 0.6% |
Similar Companies
Frequently Asked Questions
What is Infusystem Hld's annual revenue?
Infusystem Hld (INFU) reported $143.4M in total revenue for fiscal year 2025. This represents a 6.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Infusystem Hld's revenue growing?
Infusystem Hld (INFU) revenue grew by 6.4% year-over-year, from $134.9M to $143.4M in fiscal year 2025.
Is Infusystem Hld profitable?
Yes, Infusystem Hld (INFU) reported a net income of $6.6M in fiscal year 2025, with a net profit margin of 4.6%.
What is Infusystem Hld's EBITDA?
Infusystem Hld (INFU) had EBITDA of $25.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Infusystem Hld have?
As of fiscal year 2025, Infusystem Hld (INFU) had $3.2M in cash and equivalents against $19.6M in long-term debt.
What is Infusystem Hld's gross margin?
Infusystem Hld (INFU) had a gross margin of 56.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Infusystem Hld's operating margin?
Infusystem Hld (INFU) had an operating margin of 8.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Infusystem Hld's net profit margin?
Infusystem Hld (INFU) had a net profit margin of 4.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Infusystem Hld's return on equity (ROE)?
Infusystem Hld (INFU) has a return on equity of 11.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Infusystem Hld's free cash flow?
Infusystem Hld (INFU) generated $23.8M in free cash flow during fiscal year 2025. This represents a 23.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Infusystem Hld's operating cash flow?
Infusystem Hld (INFU) generated $24.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Infusystem Hld's total assets?
Infusystem Hld (INFU) had $100.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Infusystem Hld's capital expenditures?
Infusystem Hld (INFU) invested $560K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Infusystem Hld's current ratio?
Infusystem Hld (INFU) had a current ratio of 1.80 as of fiscal year 2025, which is generally considered healthy.
What is Infusystem Hld's debt-to-equity ratio?
Infusystem Hld (INFU) had a debt-to-equity ratio of 0.34 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Infusystem Hld's return on assets (ROA)?
Infusystem Hld (INFU) had a return on assets of 6.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Infusystem Hld's Altman Z-Score?
Infusystem Hld (INFU) has an Altman Z-Score of 3.77, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Infusystem Hld's Piotroski F-Score?
Infusystem Hld (INFU) has a Piotroski F-Score of 8 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Infusystem Hld's earnings high quality?
Infusystem Hld (INFU) has an earnings quality ratio of 3.68x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Infusystem Hld cover its interest payments?
Infusystem Hld (INFU) has an interest coverage ratio of 9.2x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Infusystem Hld?
Infusystem Hld (INFU) scores 52 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.